Surgical Interventions for Retinal Vascular Diseases: A Deep Dive Into the Data is organized by Healio, Vindico Medical Education.
Release Date: August 31, 2023
Expiration Date: August 31, 2024
Activity Description:
The Port Delivery System (PDS) with ranibizumab is the first approved refillable device designed to provide continuous treatment of neovascular retinal disease for 6 months or longer and has the potential to address adherence problems commonly encountered with intravitreal anti-VEGF therapy. It is currently indicated for neovascular age-related macular degeneration and is being evaluated as a treatment option for diabetic retinopathy (DR) and diabetic macular edema (DME) as well. Although the manufacturer initiated a voluntary recall of the implant and insertion tool assembly (including the drug vial and initial fill needle) due to cases of septum dislodgement, refill–exchange procedures in eligible patients who already have an implant will continue. As the PDS advances in clinical trials for its use in DR and DME, it joins other surgical-based treatments currently in phase 3 trials that also benefit from targeted subretinal administration, including gene therapy candidates such as NAV AAV8 vector RGX-314, for use in acquired retinal diseases. In addition, stem cell-based repair via subretinal injection is under investigation for geographic atrophy, and current data show early signs of effectiveness. In this educational activity, expert faculty will review the data supporting the use of the PDS with ranibizumab in vascular retinal diseases, as well as review best practices for successful refill–exchange procedures. They will also evaluate investigational surgical-based procedures that have the potential to further shape the current treatment landscape for vascular retinal diseases.
Learning Objective:
Upon successful completion of this activity, participants should be better able to:
• Assess new evidence regarding the safety and efficacy of surgically delivered medical treatments for the treatment of neovascular age-related macular degeneration (nAMD).
• Incorporate techniques and procedures that improve the refill and exchange procedure for the Port Delivery System with ranibizumab.
• Evaluate new clinical data regarding the use of surgically delivered treatments for the management of retinal vascular diseases.